Search company, investor...
ViroPharma company logo


Founded Year



Acq - P2P | Acquired

Total Raised






About ViroPharma

ViroPharma is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. ViroPharma's goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals it serves. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD).

Headquarters Location

730 Stockton Drive

Exton, Pennsylvania, 19341,

United States


Missing: ViroPharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ViroPharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ViroPharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ViroPharma is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ViroPharma Patents

ViroPharma has filed 15 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Gastrointestinal tract disorders
  • Inflammations
patents chart

Application Date

Grant Date


Related Topics




Urticaria and angioedema, Rare diseases, Psychiatric diagnosis, Syndromes, Complement system


Application Date


Grant Date



Related Topics

Urticaria and angioedema, Rare diseases, Psychiatric diagnosis, Syndromes, Complement system



Latest ViroPharma News

Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Com

Nov 2, 2022

-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology -Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. ATNM (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development assets with revenues in excess of a billion dollars. Previously, she led the chronic myelogenous leukemia (CML) portfolio, a billion-dollar business comprising TASIGNA and SCEMBLIX. She also led strategic account management during the launch period for KYMRIAH, the first approved CAR-T cell therapy. AD

ViroPharma Frequently Asked Questions (FAQ)

  • When was ViroPharma founded?

    ViroPharma was founded in 1994.

  • Where is ViroPharma's headquarters?

    ViroPharma's headquarters is located at 730 Stockton Drive, Exton.

  • What is ViroPharma's latest funding round?

    ViroPharma's latest funding round is Acq - P2P.

  • How much did ViroPharma raise?

    ViroPharma raised a total of $13.65M.

  • Who are the investors of ViroPharma?

    Investors of ViroPharma include Shire, Heights Capital Management, Angelo Gordon, Alexandra Investment Management, Centaur Performance Group. and 21 more.

  • Who are ViroPharma's competitors?

    Competitors of ViroPharma include Aerie, Longevica, Array Biopharma, BIND Therapeutics, Idenix Pharmaceuticals and 13 more.

Compare ViroPharma to Competitors


Acologix strives to improve patients' lives by developing and commercializing biopharmaceuticals targeting "osteo-renal"(bone and kidney) diseases. Acologix's deep expertise in mineral metabolism sciences is the key to solving major osteo-renal health problems. Periodontal disease, oral care, orthopedics, osteoporosis, chronic kidney disease and its secondary complications such as renal osteodystrophy and uremic pruritus represent underserved medical needs. Acologix is in its focus on these rapidly growing health care problems.

Osprey Pharmaceuticals

Osprey Pharmaceuticals is a privately held biotechnology company focused on developing and commercializing a first-in-class family of therapeutic proteins (Leukocyte Population Modulators) capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically destroy disease-related leukocytes by infiltrating the chemokine system that regulates the movement and activity of leukocytes.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.


Abunda, is a stealth mode healthcare company incubated by Burrill & Company


Solixia is a biotechnology company dedicated to helping cancer patients through the use of nanoparticle technology.

Cerecin Logo

Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment. The company was founded in 2001 and is based in Singapore.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.